165 related articles for article (PubMed ID: 30539877)
21. Osimertinib-induced severe interstitial lung disease: A case report.
Fan M; Mo T; Shen L; Yang L
Thorac Cancer; 2019 Jul; 10(7):1657-1660. PubMed ID: 31241220
[TBL] [Abstract][Full Text] [Related]
22. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W
Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891
[TBL] [Abstract][Full Text] [Related]
23. De novo Hepatitis B Virus Reactivation during Treatment with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Patient with Advanced Lung Cancer.
Horibe R; Yokota M; Uemura K; Hashimoto M; Kawagishi N; Nishiyama K
Intern Med; 2024 Jun; 63(12):1797-1800. PubMed ID: 37926534
[TBL] [Abstract][Full Text] [Related]
24. [Osimertinib Re-challenge for EGFR-mutant NSCLC after
Osimertinib-induced Interstitial Lung Disease: A Case Report].
Gu J; Bai F; Song L; Wang Y
Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):804-807. PubMed ID: 34802213
[TBL] [Abstract][Full Text] [Related]
25. A case report of toxic epidermal necrolysis associated with AZD-9291.
Wang J; Cheng X; Lu Y; Zhou B
Drug Des Devel Ther; 2018; 12():2163-2167. PubMed ID: 30034220
[TBL] [Abstract][Full Text] [Related]
26. Fingerprint loss during combination therapy using osimertinib and anlotinib: A case report.
Xie L; Feng Y; Sun J
J Clin Pharm Ther; 2022 Feb; 47(2):248-250. PubMed ID: 34240438
[TBL] [Abstract][Full Text] [Related]
27. Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
Shi P; Oh YT; Deng L; Zhang G; Qian G; Zhang S; Ren H; Wu G; Legendre B; Anderson E; Ramalingam SS; Owonikoko TK; Chen M; Sun SY
Clin Cancer Res; 2017 Nov; 23(21):6567-6579. PubMed ID: 28765329
[No Abstract] [Full Text] [Related]
28. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
[TBL] [Abstract][Full Text] [Related]
29. Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.
Huang J; Wang Y; Zhai Y; Wang J
Thorac Cancer; 2018 Jun; 9(6):745-749. PubMed ID: 29673089
[TBL] [Abstract][Full Text] [Related]
30. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
Liu Z; Gao W
Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
[TBL] [Abstract][Full Text] [Related]
31. Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment.
Chia PL; Do H; Morey A; Mitchell P; Dobrovic A; John T
Lung Cancer; 2016 Aug; 98():29-32. PubMed ID: 27393503
[TBL] [Abstract][Full Text] [Related]
32. Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.
Skoulidis F; Papadimitrakopoulou VA
Clin Cancer Res; 2017 Feb; 23(3):618-622. PubMed ID: 27821604
[TBL] [Abstract][Full Text] [Related]
33. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
34. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
[TBL] [Abstract][Full Text] [Related]
35. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
Planchard D; Loriot Y; André F; Gobert A; Auger N; Lacroix L; Soria JC
Ann Oncol; 2015 Oct; 26(10):2073-8. PubMed ID: 26269204
[TBL] [Abstract][Full Text] [Related]
36. Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer.
Häntschel M; Niebling J; Häring A; Häring MF; Groß T; Horger M; Riessen R; Haap M; Lewis RA; Böckeler M; Hetzel J
Thorac Cancer; 2020 Jul; 11(7):2044-2047. PubMed ID: 32374485
[TBL] [Abstract][Full Text] [Related]
37. Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report.
Nukii Y; Miyamoto A; Mochizuki S; Moriguchi S; Takahashi Y; Ogawa K; Murase K; Hanada S; Uruga H; Takaya H; Morokawa N; Kishi K
BMC Cancer; 2019 Feb; 19(1):186. PubMed ID: 30819142
[TBL] [Abstract][Full Text] [Related]
38. Almonertinib-induced interstitial lung disease: A case report.
Jiang T; Luo Y; Wang B
Medicine (Baltimore); 2021 Jan; 100(3):e24393. PubMed ID: 33546082
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
Wang S; Song Y; Yan F; Liu D
Front Med; 2016 Dec; 10(4):383-388. PubMed ID: 27770386
[TBL] [Abstract][Full Text] [Related]
40. Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
Xu J; Zhao X; He D; Wang J; Li W; Liu Y; Ma L; Jiang M; Teng Y; Wang Z; Gu M; Wu J; Wang Y; Yue W; Zhang S
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1413-1422. PubMed ID: 29797219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
